ONC Stock Overview
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally.
Oncimmune Holdings plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.62|
|52 Week High||UK£1.95|
|52 Week Low||UK£0.52|
|1 Month Change||-30.48%|
|3 Month Change||-29.37%|
|1 Year Change||-66.60%|
|3 Year Change||-26.86%|
|5 Year Change||-49.55%|
|Change since IPO||-53.36%|
Recent News & Updates
Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Oncimmune Holdings plc...
|ONC||GB Biotechs||GB Market|
Return vs Industry: ONC underperformed the UK Biotechs industry which returned -41.5% over the past year.
Return vs Market: ONC underperformed the UK Market which returned -16.2% over the past year.
|ONC Average Weekly Movement||11.2%|
|Biotechs Industry Average Movement||7.8%|
|Market Average Movement||5.4%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: ONC is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ONC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.
Oncimmune Holdings plc Fundamentals Summary
|ONC fundamental statistics|
Is ONC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ONC income statement (TTM)|
|Cost of Revenue||UK£2.40m|
Last Reported Earnings
May 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.14|
|Net Profit Margin||-246.49%|
How did ONC perform over the long term?See historical performance and comparison